Journal Reprints Shouldn’t See The Light Of Sunshine, Medical Societies Say
This article was originally published in The Pink Sheet Daily
Last-ditch effort to rewrite reg warns of unintended consequences from the reporting requirement.
You may also be interested in...
FDA's finalized guidance on off-label reprints contains small modifications that appear to satisfy free speech critics of the draft version. But it does not offer sufficient change to mollify congressional critics who believe the document is too permissive
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.